Personalized nutrition company Bioniq announced today the successful close of its $15 million Series B funding round. This oversubscribed round was led by prominent European venture capital firms HV Capital and Unbound. With this new funding, Bioniq’s valuation has reached $75 million, setting the stage for significant global expansion and innovation in the dietary supplements industry.
Strategic Expansion and Innovation
Founded in 2019, Bioniq has quickly gained recognition for its personalized supplements tailored to individual health needs using blood biomarker data. The fresh capital injection will enable Bioniq to extend its market reach and develop new products. Key focus areas include:
Global Laboratory Network Integrations: Enhancing its ability to provide precise, data-driven supplement recommendations by integrating with more labs worldwide.
Market and Operational Expansion: Targeting the U.S. and Middle East for further growth, aiming to tap into these burgeoning markets more effectively.
Human Resources Expansion: Scaling teams to support the increasing demand and operational complexity.
Corporate Platform Development: Creating a dedicated platform for medical, wellness, and athletic institutions, enhancing the accessibility and applicability of its products.
Bioniq officially entered the UAE market in 2021 and has since expanded across the Gulf region. The company has forged strategic partnerships with key organizations, including the Department of Culture and Tourism – Abu Dhabi, Metabolic, and Al Borg Diagnostics in Saudi Arabia. These alliances are crucial in bolstering the personalized health and wellness sectors in these regions.
U.S. Market Leads the Charge
The U.S. has emerged as Bioniq’s largest market, accounting for over 50% of its customer base. Demand has surged, with some regions experiencing over 500% growth in the last two quarters. Bioniq’s ability to deliver quantifiable results through personalized supplements has attracted partnerships with leading health and sports institutions, such as Lanserhof and UFC. Prominent athletes, including Manchester United’s Diogo Dalot and former NBA All-Star Andrei Kirilenko, rely on Bioniq to optimize their performance and recovery.
Personalized Health Solutions
Bioniq’s innovative approach leverages its extensive biochemical database and AI-driven technology to create tailored supplement formulas. The company offers two primary products:
Bioniq PRO: Designed for high performers and health enthusiasts, this service integrates blood biomarker data into its algorithm. Users can upload existing bloodwork or book a blood test through partner labs. The data is analyzed to create a personalized daily supplement formula, supplemented by 1:1 nutrition consultations with a Registered Dietitian.
Bioniq GO: A more accessible option, utilizing a questionnaire-driven AI algorithm to recommend a unique supplement blend based on users’ responses and historical blood biomarker data.
All Bioniq supplements are Swiss-made, pharmaceutical-grade, and utilize precise micro-dosing to address individual needs. The supplements are delivered in patented prebiotic guar granules, designed to mimic natural digestion, thereby maximizing bioavailability and minimizing nutrient competition.
David Kuczek, General Partner at HV Capital, praised Bioniq’s innovative approach and exceptional growth.
“Bioniq's exceptional growth is a testament to its innovative approach for high-quality personalized health solutions that professional athletes across the world rely on,” he said.
Shravin Mittal, CEO of Unbound, added, “Bioniq is disrupting the supplement industry with their personalized and science-based approach. We are excited to support them as they grow and scale their business."
Bioniq’s vision for the future is clear: to lead the charge in personalized nutrition by providing advanced, adaptable products that cater to individual health journeys. With its new funding and strategic plans, Bioniq is poised to continue its rapid expansion and set new standards in the dietary supplements market.
Bioniq’s successful Series B funding round marks a significant milestone in its mission to revolutionize the dietary supplements market. With a strong focus on personalized health solutions backed by cutting-edge technology and strategic partnerships, Bioniq is well-positioned to lead the future of nutritional supplementation. As it expands its global footprint and enhances its product offerings, Bioniq continues to set a new benchmark for the industry, promising more personalized, effective, and transparent health solutions for its growing customer base.